Man Group plc Has $12.07 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Man Group plc decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 50.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 167,368 shares of the medical equipment provider's stock after selling 172,020 shares during the period. Man Group plc owned 0.07% of Hologic worth $12,066,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HOLX. Norges Bank bought a new stake in Hologic during the 4th quarter worth about $133,414,000. Boston Partners raised its holdings in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Champlain Investment Partners LLC bought a new stake in Hologic during the 4th quarter worth about $79,291,000. Northern Trust Corp raised its holdings in Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after purchasing an additional 668,086 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after purchasing an additional 572,187 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent research reports. Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. William Blair reissued an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $77.42.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.88% of the stock is owned by insiders.

Hologic Price Performance

Shares of HOLX opened at $56.79 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a 50 day simple moving average of $58.76 and a 200 day simple moving average of $67.32. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market capitalization of $12.66 billion, a PE ratio of 17.91, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the firm earned $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.